Prostate Cancer

A recent study showed the capacity to classify metastatic castration-resistant prostate tumors as luminal and basal, and examined the personalized medicine potential unlocked by identifying these subtypes.

“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.

"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.

“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.

"What we still need to trial is the use of treatment intensification or triple therapy in men with high-risk localized and/or locally advanced disease," writes Michael S. Cookson, MD, MMHC.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

"One of the main goals of our interactions with patients is to increase adherence," said Amy Pfeifer, PharmD, BCPS, CSP.

"We believe this novel treatment strategy will improve the lives of many prostate cancer patients,” said lead study investigator Behfar Ehdaie, MD.

The phase 3 PROpel trial showed that adding the PARP inhibitor olaparib to frontline abiraterone acetate significantly improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Eric J. Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.

The Moffitt research team, in collaboration with scientists at Washington University in St. Louis, wanted to identify alternative resistance mechanisms to enzalutamide and abiraterone in prostate cancer patients.

Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.

Proteolysis-targeting chimaera, or PROTACs, work by using elements of the body’s natural protein recycling system and recruiting them toward cancerous proteins

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies.

The median time between PSA progression and metastasis was 7.0 months for darolutamide compared with 5.6 months for placebo.

“Darolutamide, unlike enzalutamide, does not affect cabazitaxel systemic exposure, justifying their use in combination,” the authors wrote in their poster.

“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.

"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.

In this video, Adam S. Kibel, MD, discusses the development of transrectal ultrasound-guided prostate biopsy and how prostate biopsy has continued to evolve over the years.

“Using the single-port robot with the transvesical approach allows us to go directly into the bladder, this means that we avoid the intraperitoneal cavity, which is not feasible with the multiport approach. This has led to less pain and postoperative ileus because the bowels stay intact,” says Jihad Kaouk, MD.

On this episode of Cleveland Clinic’s Cancer Advances podcast, Zeyad Schwen, MD, discusses transperineal biopsy and advancements in screening for prostate cancer.

“We need to address the issue of therapy resistance, as it may become a larger problem in the future,” said Sarki Abdulkadir, MD, PhD.

Prostate tumors are among the cancers for whom this novel therapy is being explored.

"The true innovation is finding better ways to do focal therapy that decreases the side effects for the patients and still treats the lesion effectively," says Jennifer A. Linehan, MD.

Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.